Besides the deregulation of ATPase gene expression after treatment with retinoids, ATRA and its analogues were found to be substrates for the MDR transporters and thus exposed to variations in their intracellular concentration leading to pharmacokinetic disturbances and variable anti-cancer response [13,14]. The gene discussed is DNAH8; the disease is cancer.